REFERENCES
- Kozin F, Fowler M, Koethe SM. A comparisonof the sensitivities and specificities of different substrates for the fluorescent antinuclear anti-body test. Am J Clin Pathol 1980; 74: 785–90.
- Tan EM, Feltkamp TEW, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinu-clear antibodies in "healthy" individuals. Arthri-tis Rheum 1997;40: 1601–11.
- Feltkamp TEW. Antinuclear antibody determi-nation in a routine laboratory. Ann Rheum Dis 1996; 55: 723–7.
- Jaskowski TD, Schroder C, Martins TB, Mour-istsen CL, Litwin CM, Hill HR. Screening for antinuclear antibodies by enzyme immunoassay. Am J Clin Pathol 1996; 105: 468–73.
- Hombburger HA, Cahen YD, Griffiths J, Jacob GL. Detection of antinuclear antibodies: Com-parative evaluation of enzyme immunoassay and indirect immunofluorescence methods. Arch Pathol Lab Med 1998; 122: 993–9.
- Emlen W, O'Neill L. Clinical significance of antinuclear antibodies:comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum 1997; 40: 1612–8.
- Bayer PM, Bauerfeind S, Bienvenu J, Fabien N, Frei PC, Gilburd B,et al. Multicenter evaluation study on a new HEp2 ANA screening enzyme Immune assay. J Autoimmun 1999; 13: 89–93.
- Kumagai S, Kanagawa S, Morinobu A, Takada M, Nakamura K, Sugai S, et al. Association of a new allele of the TAP2 gene, TAP2*Bky2 (Val-577), with susceptibility to Sjogren's syndrome. Arthritis Rheum 1997; 40: 1685-1692.
- Koch GG, Landis JR, Freeman DH Jr, Lehnen RC. A general methodology for the analysis of experiments with repeated measurement of cate-gorical data. Biometrics 1977; 33: 133–58.
- Reisner BS, DiBlasi J, Goel N. Comparison of an enzyme immunoassay to an indirect fluores-cent immunoassay for the detection of antinu-clear antibodies. Am J Clin Pathol 1999; 111: 503–6.